ICO SEGURO® … a comprehensive program for the management of anal pathology caused by Human Papillomavirus infection. Experience of a Reference Center

Authors

DOI:

https://doi.org/10.22516/25007440.1538

Keywords:

Human papillomavirus, anoscopy, human immunodeficiency virus, anal dysplasia, anal cancer

Abstract

Objective: To describe the clinical outcomes of the ICO SEGURO® program in the management of HPV-related anal pathology in high-risk patients (January 2022 – June 2025).

 

Design: Retrospective cohort descriptive study, single referral center, Medellín, Colombia.

 

Participants: 6,671 patients undergoing high-resolution anoscopy (HRA), 90% male, predominantly aged 20–40 years, metropolitan area of ​​the Aburrá Valley.

 

Intervention/Main Outcomes: Ablative therapy using electrofulguration (74%), medical ablative therapy (MAT) with 5-fluorouracil (5-FU) + methotrexate (9%), HRA with no findings (17%). Lesion resolution rate with MAT: 73.4%. Progression rate to squamous cell carcinoma: 0.2%.

 

Conclusion: AAR guided by the ICO classification is an effective strategy for the diagnosis and stepwise treatment of premalignant anal lesions in high-risk populations, with resolution rates comparable to or higher than those reported in the international literature.

Downloads

Download data is not yet available.

Author Biographies

Juan Ricardo Márquez Velásquez, Instituto de Coloproctología (ICO)

Coloproctólogo. Medellín, Colombia.

Luis Francisco Miranda Ruíz, Instituto de Coloproctología (ICO)

Coloproctólogo. Medellín, Colombia.

Lina María Mateus Barbosa, Instituto de Coloproctología (ICO)

Coloproctólogo. Medellín, Colombia.

Nathalie Carolina Villan Ramírez, Instituto de Coloproctología (ICO)

Coloproctólogo. Medellín, Colombia.

Jorge Iván Sierra Jaramillo, Instituto de Coloproctología (ICO)

Coloproctólogo. Medellín, Colombia.

Daniel González Nuñez, Instituto de Coloproctología (ICO)

Especialista en coloproctología. Medellín, Colombia.

Sebastián Grisales Ramirez, Instituto de Coloproctología (ICO)

Especialista en entrenamiento de Coloproctología, FUCS Bogotá. Medellín, Colombia.

Paola Stephany González A, Instituto de Coloproctología (ICO)

Cirujana General. Medellín, Colombia.

María Antonia Velásquez Martínez, Instituto de Coloproctología (ICO)

Cirujana General. Medellín, Colombia.

Carlos Andrés Miranda Ruíz, Instituto de Coloproctología (ICO)

Médico General. Medellín, Colombia.

References

Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, Liu Y, Poynten IM, et al. International Anal Neoplasia Society’s consensus guidelines for anal cancer screening. Int J Cancer. 2024;154(10):1694-702. https://doi.org/10.1002/ijc.34850

Gobernación de Antioquia, Departamento Administrativo de Planeación, Escuela de Gobierno y Políticas Públicas de Antioquia. Elementos básicos de planificación zonal y subregional en el departamento de Antioquia. Medellín: GdA-DAP; 2008.

Ruel J, Ko HM, Roda G, Patil N, Zhang D, Jharap B, et al. Anal Neoplasia in Inflammatory Bowel Disease Is Associated With HPV and Perianal Disease. Clin Transl Gastroenterol. 2016;7(3):e148. https://doi.org/10.1038/ctg.2016.8

Roberts JR, Siekas LL, Kaz AM. Anal intraepithelial neoplasia: A review of diagnosis and management. World J Gastrointest Oncol. 2017;9(2):50-61. https://doi.org/10.4251/wjgo.v9.i2.50

Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011;204(4):566-73. https://doi.org/10.1093/infdis/jir341

Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med. 2007;15(4):130-3.

Poggio JL. Premalignant lesions of the anal canal and squamous cell carcinoma of the anal canal. Clin Colon Rectal Surg. 2011;24(3):177-92. https://doi.org/10.1055/s-0031-1286002

Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177(2):361-7. https://doi.org/10.1086/514194

Lacey HB, Wilson GE, Tilston P, Wilkins EG, Bailey AS, Corbitt G, et al. A study of anal intraepithelial neoplasia in HIV positive homosexual men. Sex Transm Infect. 1999;75(3):172-7. https://doi.org/10.1136/sti.75.3.172

Palefsky JM, Holly EA, Efird JT, Da Costa M, Jay N, Berry JM, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS. 2005;19(13):1407-14. https://doi.org/10.1097/01.aids.0000181012.62385.4a

Piketty C, Darragh TM, Heard I, Da Costa M, Bruneval P, Kazatchkine MD, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis. 2004;31(2):96-9. https://doi.org/10.1097/01.OLQ.0000109515.75864.2B

Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004;37(5):1563-5. https://doi.org/10.1097/00126334-200412150-00004

Deshmukh AA, Damgacioglu H, Georges D, Sonawane K, Ferlay J, Bray F, et al. Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis. Int J Cancer. 2023;152(3):417-28. https://doi.org/10.1002/ijc.34269

Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer. 2021;148(1):38-47. https://doi.org/10.1002/ijc.33185

Wieland U, Brockmeyer NH, Weissenborn SJ, Hochdorfer B, Stücker M, Swoboda J, et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol. 2006;142(11):1438-44. https://doi.org/10.1001/archderm.142.11.1438

Palefsky JM, Lee JY, Jay N, Goldstone SE, Darragh TM, Dunlevy HA, et al. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. N Engl J Med. 2022;386(24):2273-82. https://doi.org/10.1056/NEJMoa2201048

Goldstone SE, Johnstone AA, Moshier EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. Dis Colon Rectum. 2014;57(3):316-23. https://doi.org/10.1097/DCR.0000000000000058

Hirsch B, Vail RM, Shah SS, Fine SM, McGowan JP, Merrick ST, et al. Screening for Anal Dysplasia and Cancer in Adults With HIV. NYSDOH AIDS INSTITUTE GUIDELINE: Clinical Guidelines Program; febrero de 2025 [citado el 1 de octubre de 2026]. Disponible en: https://www.hivguidelines.org/guideline/hiv-anal-cancer/#toc_wurop7uf

Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: A review. World J Gastrointest Surg. 2016;8(1):41-51. https://doi.org/10.4240/wjgs.v8.i1.41

Albuquerque A. High-resolution anoscopy: Unchartered territory for gastroenterologists? World J Gastrointest Endosc. 2015;7(13):1083-7. https://doi.org/10.4253/wjge.v7.i13.1083

Berry JM, Palefsky JM, Welton ML. Anal cancer and its precursors in HIV-positive patients: perspectives and management. Surg Oncol Clin N Am. 2004;13(2):355-73. https://doi.org/10.1016/j.soc.2003.12.003

Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum. 2002;45(4):453-8. https://doi.org/10.1007/s10350-004-6219-8

Chin-Hong PV, Palefsky JM. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol Ther. 2005;18(1):67-76. https://doi.org/10.1111/j.1529-8019.2005.05009.x

Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum. 2005;48(5):1042-54. https://doi.org/10.1007/s10350-004-0889-0

Özkaya DB, Erfan G, Çıtamak B. The effectiveness of genital wart treatments. J Urol Surg. 2023;10(3):179–88. https://doi.org/10.4274/jus.galenos.2023.2023-6-8

Kosmidis C, Sevva C, Magra V, Varsamis N, Koulouris C, Charalampous I, et al. HPV-Induced Anal and Peri-Anal Neoplasia, a Surgeon’s Experience: 5-Year Case Series. Diagnostics (Basel). 2023;13(4):702. https://doi.org/10.3390/diagnostics13040702

Long KC, Menon R, Bastawrous A, Billingham R. Screening, Surveillance, and Treatment of Anal Intraepithelial Neoplasia. Clin Colon Rectal Surg. 2016;29(1):57-64. https://doi.org/10.1055/s-0035-1570394

Figura 1. Departamento de Antioquia, subregiones y zonas. *Número de municipios. Tomada de: Gobernación de Antioquia, et al. Medellín: GdA-DAP; 2008(2).

Published

2026-11-13

How to Cite

Márquez Velásquez, J. R., Miranda Ruíz, L. F., Mateus Barbosa, L. M., Villan Ramírez, N. C., Sierra Jaramillo, J. I., González Nuñez, D., … Miranda Ruíz, C. A. (2026). ICO SEGURO® … a comprehensive program for the management of anal pathology caused by Human Papillomavirus infection. Experience of a Reference Center. Revista Colombiana De Gastroenterología, 41(4), 438–446. https://doi.org/10.22516/25007440.1538

Issue

Section

Originals articles

Altmetric

Escanea para compartir
QR Code
Crossref Cited-by logo
Article metrics
Abstract views62
Galley views15
PDF Views15
HTML views0
Other views0

Some similar items: